Abionyx Pharma H1 FY26 net loss widens to €4.81 million; revenue slips 8.96% to €1.93 million
Bitget2026/09/23 19:36- Abionyx Pharma posted a first-half net loss of €4.81 million, widening from €2.31 million a year earlier.
- Revenue slipped 8.96% to €1.93 million, attributed solely to IRIS Pharma’s ophthalmology CRO business.
- Operating loss narrowed to €2.27 million, while the financial result swung to a €2.54 million loss.
- Financial result included €1.6 million in expense from fair-value measurement of Fenja straight bonds and issuance costs.
- Cash and equivalents rose to €26.87 million; €6.2 million of a €8.7 million France 2030 sepsis award remains to be received.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
